Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMPAGLIFLOZIN; LINAGLIPTIN vs DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
10 mg empagliflozin/5 mg linagliptin orally once daily.
Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.
Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life).
Dapagliflozin: Terminal half-life ~12.9 hours (supports once-daily dosing). Saxagliptin: Terminal half-life ~2.5 hours, but active metabolite 5-hydroxy saxagliptin has half-life ~3.1 hours (supports once-daily dosing due to prolonged DPP-4 inhibition).
Empagliflozin is primarily metabolized via glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9) with minor CYP450 involvement. Linagliptin is minimally metabolized; approximately 90% is excreted unchanged via enterohepatic system (biliary excretion) and renal elimination is negligible.
Dapagliflozin is primarily metabolized via glucuronidation by UGT1A9; saxagliptin is metabolized via CYP3A4/5 to an active metabolite.
Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal.
Dapagliflozin: ~75% renal excretion (21% unchanged, 50% as major metabolite 3-O-glucuronide), ~21% fecal. Saxagliptin: ~75% renal excretion (12% unchanged, 22% as major metabolite 5-hydroxy saxagliptin, 41% as other metabolites), ~22% fecal.
Empagliflozin: ~86.2% (primarily albumin). Linagliptin: 70-80% (concentration-dependent, saturable binding to DPP-4; also albumin).
Dapagliflozin: ~91% bound primarily to albumin. Saxagliptin: Negligible (<10% bound).
Empagliflozin: Vd/F ~9.6 L (0.14 L/kg; extensive tissue distribution). Linagliptin: Vd ~1000 L (14 L/kg; large due to extensive tissue binding).
Dapagliflozin: Vd ~118 L (1.5 L/kg based on 70 kg, indicating extensive extravascular distribution). Saxagliptin: Vd ~71 L (1.0 L/kg based on 70 kg, indicating distribution into tissues).
Empagliflozin: oral bioavailability ~78% (high, unaffected by food). Linagliptin: oral bioavailability ~30% (food has no effect; low due to first-pass and saturable absorption).
Dapagliflozin: Oral bioavailability ~78% (high, influenced by food). Saxagliptin: Oral bioavailability ~75% (high, not significantly affected by food).
Contraindicated if e GFR < 30 m L/min/1.73 m². Not recommended if e GFR < 45 m L/min/1.73 m². No dose adjustment for e GFR ≥ 45 m L/min/1.73 m².
e GFR ≥45 m L/min/1.73 m²: No dose adjustment. e GFR 30–44 m L/min/1.73 m²: Not recommended due to limited data for saxagliptin. e GFR <30 m L/min/1.73 m²: Contraindicated due to dapagliflozin; do not initiate, discontinue if e GFR falls below 30.
No dose adjustment required for mild, moderate, or severe hepatic impairment (Child-Pugh A, B, C).
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B: Not recommended for saxagliptin (limited data) and caution for dapagliflozin. Child-Pugh Class C: Contraindicated or not recommended.
Safety and efficacy not established in pediatric patients.
Not established. Safety and efficacy in pediatric patients (<18 years) have not been studied.
No dose adjustment based on age alone. Assess renal function; contraindicated if e GFR < 30 m L/min/1.73 m². Consider increased risk of volume depletion and hypotension in patients aged ≥75 years.
No specific dose adjustment; monitor renal function (e.g., e GFR) and volume status due to age-related decrease in renal function and increased risk of hypotension, dehydration, and acute kidney injury.
None
There is no black box warning for this combination product.
Risk of pancreatitis (linagliptin),Risk of genital mycotic infections and urinary tract infections (empagliflozin),Risk of volume depletion, hypotension, and acute kidney injury (empagliflozin),Risk of ketoacidosis, including euglycemic ketoacidosis (empagliflozin),Risk of hypoglycemia when used with insulin or sulfonylureas,Risk of heart failure (linagliptin; postmarketing reports),Risk of bullous pemphigoid (DPP-4 inhibitors),Risk of severe and disabling arthralgia (DPP-4 inhibitors)
Pancreatitis,Heart failure,Hypoglycemia when used with insulin or insulin secretagogues,Acute kidney injury,Genital mycotic infections,Urinary tract infections,Hypotension,Ketoacidosis,Necrotizing fasciitis of the perineum (Fournier’s gangrene),Arthralgia,Bullous pemphigoid
History of serious hypersensitivity reaction to empagliflozin, linagliptin, or any excipient,Severe renal impairment (e GFR < 30 m L/min/1.73 m²), end-stage renal disease, or dialysis (empagliflozin),Type 1 diabetes mellitus (empagliflozin; risk of ketoacidosis)
History of serious hypersensitivity reaction to dapagliflozin, saxagliptin, or any component,Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease,Diabetic ketoacidosis,Type 1 diabetes mellitus
No significant food interactions. Alcohol may increase risk of lactic acidosis and ketoacidosis; limit intake. Avoid grapefruit juice as it may affect linagliptin metabolism (minor interaction, but caution advised).
No specific food restrictions; alcohol may increase hypoglycemia risk.
Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are maturing. Human data are limited; however, SGLT2 inhibitors are generally avoided in the second and third trimesters due to potential risk of acute kidney injury in neonates. Linagliptin: Animal studies have shown no evidence of teratogenicity at clinically relevant doses. Human data are insufficient; however, DPP-4 inhibitors are generally considered low risk during pregnancy. Overall, combination should be avoided unless clearly needed, particularly in the second and third trimesters.
Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformations but potential for delayed ossification at high doses. First trimester: Use only if clearly needed; no well-controlled human studies. Second and third trimesters: Dapagliflozin not recommended; avoid.
Empagliflozin: Unknown if excreted in human milk; animal studies show excretion in milk. Due to potential for adverse effects on the developing infant (e.g., renal effects), breastfeeding is not recommended. Linagliptin: Unknown if excreted in human milk; animal studies show low levels in milk. Caution is advised. Both drugs: M/P ratio not available. Manufacturer recommends discontinuing drug or breastfeeding.
No data on excretion in human milk. Dapagliflozin is present in rat milk; saxagliptin is excreted in rat milk. M/P ratio unknown. Caution advised due to potential for adverse effects in nursing infant.
Empagliflozin: Pregnancy alters pharmacokinetics (increased renal clearance, volume of distribution), but no specific dose adjustments are recommended due to lack of data. However, empagliflozin is contraindicated in pregnancy, particularly in the second and third trimesters. Linagliptin: No dose adjustment required based on pharmacokinetic changes in pregnancy; however, safety data are limited. Overall, alternative therapies are preferred during pregnancy.
No specific dose adjustments established for pregnancy. Dapagliflozin is not recommended in pregnancy; consider alternative therapy. Saxagliptin: dose adjustment not required based on pharmacokinetic changes; however, lack of data limits recommendation.
Empagliflozin/linagliptin should not be used in patients with type 1 diabetes or for diabetic ketoacidosis treatment. Assess renal function before initiation and periodically; e GFR <45 m L/min/1.73 m2 is a contraindication for empagliflozin. Monitor for signs of ketoacidosis, even if blood glucose is not markedly elevated. Linagliptin does not require dose adjustment for renal impairment. Genital mycotic infections and urinary tract infections are common with empagliflozin; counsel on hygiene. Temporary discontinuation of SGLT2 inhibitors is recommended before surgery or during prolonged fasting to reduce ketoacidosis risk.
Monitor renal function before initiation and periodically; contraindicated if e GFR <45 m L/min/1.73 m². Assess volume status due to diuretic effect. Watch for pancreatitis and hypersensitivity. Adjust insulin or sulfonylurea doses to reduce hypoglycemia risk. Discontinue if pancreatitis suspected. T1DM is not an indication.
Take this medication exactly as prescribed, usually once daily with or without food.,Stay well hydrated to reduce risk of dehydration and urinary tract infections.,Report symptoms of genital itching, discomfort, or discharge promptly for possible yeast infection.,Seek immediate medical attention if you experience symptoms of ketoacidosis (nausea, vomiting, abdominal pain, confusion, unusual fatigue, difficulty breathing) even if blood sugar is normal.,Do not share this medication with others; it is not for treating type 1 diabetes.,Inform all healthcare providers that you are taking this medication, especially before surgery or procedures.
Take once daily with or without food; swallow tablets whole.,Stay hydrated to prevent dehydration from increased urination.,Genital mycotic infections may occur; report any symptoms.,Severe joint pain possible; advise seeking medical attention.,Do not share insulin pens or needles.,Store medication at room temperature away from moisture and heat.
"Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption, leading to decreased blood glucose levels. Rosoxacin, a quinolone antibiotic, may enhance the hypoglycemic effects of empagliflozin by potentiating insulin secretion or improving insulin sensitivity, which could increase the risk of hypoglycemic episodes, especially in patients with diabetes mellitus."
"Quinethazone, a thiazide-like diuretic, reduces intravascular volume and may blunt the osmotic diuretic effect of empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, thereby decreasing empagliflozin's efficacy in lowering blood glucose. This interaction is mediated through volume contraction leading to reduced renal perfusion and diminished glucose excretion. Clinically, patients may experience higher-than-expected blood glucose levels, potentially compromising glycemic control."
"Concomitant use of lisinopril, an angiotensin-converting enzyme inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 inhibitor, may enhance the risk of hypotension, acute kidney injury, and hyperkalemia. Lisinopril reduces angiotensin II-mediated vasoconstriction and aldosterone secretion, which can be compounded by empagliflozin-induced volume depletion and osmotic diuresis. This interaction is particularly concerning in patients with renal impairment or those on other medications affecting the renin-angiotensin-aldosterone system."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin levels leading to glucose-dependent insulin secretion, while Milnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may independently affect glucose homeostasis. Concurrent use could theoretically increase the risk of hypoglycemia due to additive effects on insulin secretion or glucose metabolism, although clinical data are limited. Patients should be monitored for signs of hypoglycemia, especially if also on other glucose-lowering agents."
"Tolazamide, a sulfonylurea, increases insulin secretion from pancreatic beta cells, while saxagliptin, a DPP-4 inhibitor, prolongs the action of incretin hormones (GLP-1 and GIP) to enhance glucose-dependent insulin release. When coadministered, the complementary mechanisms can lead to additive hypoglycemic effects, significantly increasing the risk of hypoglycemia, particularly in patients with renal impairment or those on irregular meal schedules."
"Saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been reported to potentially reduce the systemic exposure of theophylline, a xanthine bronchodilator, likely through the induction of cytochrome P450 (CYP) 1A2, the primary enzyme responsible for theophylline metabolism. This interaction may lead to subtherapeutic theophylline concentrations, resulting in decreased bronchodilator efficacy and potential exacerbation of respiratory symptoms, particularly in patients with asthma or chronic obstructive pulmonary disease. The effect appears to be modest but may be clinically relevant in patients requiring stable theophylline levels."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMPAGLIFLOZIN; LINAGLIPTIN vs DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE, answered by our medical review team.
EMPAGLIFLOZIN; LINAGLIPTIN is a DPP-4 Inhibitor that works by Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.. DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is a DPP-4 Inhibitor that works by Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal renal tubule, reducing plasma glucose independent of insulin secretion. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs incretin hormone activity, increasing insulin release and decreasing glucagon secretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMPAGLIFLOZIN; LINAGLIPTIN and DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE depend on the specific clinical indication. These are both DPP-4 Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMPAGLIFLOZIN; LINAGLIPTIN is: 10 mg empagliflozin/5 mg linagliptin orally once daily.. The standard adult dose of DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is: Oral: 1 tablet (dapagliflozin 5 mg / saxagliptin 5 mg) once daily, taken with or without food, in combination with metformin or other glucose-lowering agents.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining EMPAGLIFLOZIN; LINAGLIPTIN and DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. EMPAGLIFLOZIN; LINAGLIPTIN is classified as Category A/B. Empagliflozin: Based on animal studies, empagliflozin may cause renal toxicity in the developing fetus, particularly during the second and third trimesters when fetal kidneys are m. DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE is classified as Category A/B. Dapagliflozin is contraindicated in the second and third trimesters due to risk of fetal renal toxicity. Saxagliptin has limited human data; animal studies show no major malformati. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.